Bayer Animal Health is planning the November release of Claro Otic Solution, a single-dose drug indicated for the treatment of canine ear inflammation and infections. Claro (florfenicol, terbinafine, mometasone furoate) is proven effective against susceptible strains of common pathogens found in canine otitis externa, Bayer reported today. The clear liquid contains antibacterial, antifungal and anti-inflammatory ingredients. The drug is intended for in-clinic use. “This new, unique treatment eliminates veterinarian uncertainty about pet owner compliance and spares pet owners the frustrations of in-home application and multiple treatment visits,” Bayer stated. Claro works on susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius), the manufacturer noted. The drug should not be used on dogs hypersensitive to the active ingredients or with perforated tympanic membranes. Otitis externa is the second most common reason dog owners take their pet to a veterinarian, according to Shawnee, Kan.-based Bayer. Claro will compete with another recently released canine ear infection drug. Elanco Animal Health in August launched Osurnia, a two-dose gel containing florfenicol, terbinafine and betamethasone acetate.
